sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Prepares for Bird Flu Fight with NV-387
On February 11, 2025, NanoViricides, Inc. announced its preparedness to tackle the bird flu with NV-387, its broad-spectrum antiviral drug. NV-387 is projected to thwart the H5N1 virus, even during rapid mutations. This announcement followed an article in Scientific American critiquing the US's readiness for a human bird flu pandemic.
The company argues that previous vaccine strategies were insufficient during the COVID-19 pandemic, as the ever-evolving virus outpaced vaccine development. NanoViricides advocates for its antiviral solution, NV-387, which has shown efficacy against multiple viruses, including different flu strains and coronaviruses.
Highlighting the potential threat posed by bird flu, NanoViricides emphasizes the importance of a quick response in pandemic preparedness. With no substantial human-to-human transmission yet, the emphasis remains on preemptive measures.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.